#ACR21 #Abstr1484 Hands down one of the most impressive results and trial design. RHAPSODY: Rilonacept led to ⬇️risk of pericarditis recurrence vs PBO (7% vs 74%; HR 0.04). Median time to resolution of pain and CRP were 5 & 7 Days. FDA approved @RheumNow https://t.co/Zty2WnkJEQ https://t.co/xGqt9Lwvjj
Links:
RHAPSODY: Rilonacept, an IL-1α and IL-1β Trap, Resolves Pericarditis Episodes a…
https://bit.ly/3c96RTv
08-11-2021
